Immunohistochemical analysis of E-cadherin and zeste homolog 2 expression in endoscopic ultrasound-guided fine-needle aspiration of pancreatic adenocarcinoma

Cancer Cytopathology

Volumn 121, Issue 11, 2013, Pages 644-652

  Gao, Ling ^a   Antic, Tatjana ^a   Hyjek, Elizabeth ^a   Gong, Can ^a   Mueller, Jeffrey ^a   Waxman, Irving ^a   DeMay, Richard M ^a   Reeves, Ward ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adenocarcinoma; E cadherin; EZH2; Immunohistochemistry; Ultrasound guided fine needle aspiration; Zeste homolog 2

Indexed keywords

BIOLOGICAL MARKER; PARAFFIN; TRANSCRIPTION FACTOR EZH2; TUMOR MARKER; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURGERY; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR CELL; TUMOR LOCALIZATION;

ADENOCARCINOMA; E-CADHERIN; EZH2; IMMUNOHISTOCHEMISTRY; ULTRASOUND-GUIDED FINE-NEEDLE ASPIRATION; ZESTE HOMOLOG 2;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84888288022     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21310     Document Type: Article

References (18)

1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012.
2. Hasan MK, Hawes RH. EUS-guided FNA of solid pancreas tumors. Gastrointest Endosc Clin North Am. 2012;22: 155-167.
3. Ansari D, Rosendahl A, Elebro J, Andersson R. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg. 2011;98: 1041-1055.
4. Semb H, Christofori G. The tumor-suppressor function of E-cadherin. Am J Hum Genet. 1998;63: 1588-1593.
5. Hong SM, Li A, Olino K, et al. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Mod Pathol. 2011;24: 1237-2147.
6. Jamieson NB, Carter CR, McKay CJ, Oien KA. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res. 2011;17: 3316-3331.
7. Carbone C, Moccia T, Zhu C, et al. Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin Cancer Res. 2011;17: 5822-5832.
8. Krantz SB, Shields MA, Dangi-Garimella S, Munshi HG, Bentrem DJ. Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res. 2012;173: 105-112.
9. Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69: 5820-5828.
10. Albert M, Helin K. Histone methyltransferases in cancer. Semin Cell Dev Biol. 2010;21: 209-220.
11. Toll AD, Dasgupta A, Potoczek M, et al. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol. 2010;41: 1205-1209.
12. Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res. 2008;14: 6790-6796.
13. Rachagani S, Senapati S, Chakraborty S, et al. Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br J Cancer. 2011;104: 1038-1048.
14. Avan A, Crea F, Paolicchi E, et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther. 2012;11: 1735-1746.
15. Fujii S, Fukamachi K, Tsuda H, Ito K, Ito Y, Ochiai A. RAS oncogenic signal upregulates EZH2 in pancreatic cancer. Biochem Biophys Res Commun. 2012;417: 1074-1079.
16. Fujii S, Tokita K, Wada N, et al. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene. 2011;30: 4118-4128.
17. Mallen-St Clair J, Soydaner-Azeloglu R, Lee KE, et al. EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev. 2012;26: 439-444.
18. Lasfargues C, Pyronnet S. EZH2 links pancreatitis to tissue regeneration and pancreatic cancer. Clin Res Hepatol Gastroenterol. 2012;36: 323-324.